INT51837

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1995
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 17
Total Number 18
Disease Relevance 6.50
Pain Relevance 9.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (TACR1) cytoplasm (TACR1) signal transducer activity (TACR1)
Anatomy Link Frequency
AT-1 1
foot 1
prefrontal 1
TACR1 (Homo sapiens)
Pain Link Frequency Relevance Heat
substance P 183 100.00 Very High Very High Very High
antagonist 127 100.00 Very High Very High Very High
Opioid 4 100.00 Very High Very High Very High
gABA 2 100.00 Very High Very High Very High
Neurotransmitter 6 99.96 Very High Very High Very High
Lasting pain 3 99.84 Very High Very High Very High
Kinase C 13 99.80 Very High Very High Very High
Pain 9 99.52 Very High Very High Very High
Cannabinoid 2 98.40 Very High Very High Very High
beta blocker 6 98.28 Very High Very High Very High
Disease Link Frequency Relevance Heat
Cough 12 100.00 Very High Very High Very High
Pain 12 99.84 Very High Very High Very High
Hypertension 5 99.00 Very High Very High Very High
Vomiting 154 98.70 Very High Very High Very High
Anxiety Disorder 3 97.12 Very High Very High Very High
INFLAMMATION 123 94.80 High High
Headache 11 91.52 High High
Lower Respiratory Tract Infection 1 90.08 High High
Dizziness 7 87.20 High High
Heart Rate Under Development 3 87.16 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Ventromedial prefrontal neurokinin 1 receptor availability is reduced in chronic pain.
Negative_regulation (reduced) of neurokinin 1 receptor in prefrontal associated with pain and lasting pain
1) Confidence 0.43 Published 2010 Journal Pain Section Title Doc Link 20137858 Disease Relevance 0.69 Pain Relevance 0.89
Since a rapid NK1 receptor desensitization has been reported in human isolated bronchi [22], and in order to clarify the role of the NK1 receptor in the responses to hHK-1, we compared the effects of single or cumulative additions of hHK-1 and of the specific NK1 receptor agonist [Sar9,Met(O2)11] SP.
Negative_regulation (desensitization) of NK1 receptor associated with agonist and substance p
2) Confidence 0.41 Published 2010 Journal Respir Res Section Body Doc Link PMC2959027 Disease Relevance 0 Pain Relevance 0.33
Specific receptor subtypes have been associated with the suppression of cough at central sites, including 5-HT1A, opioid (mu, kappa, and delta), GABA-B, tachykinin neurokinin-1 (NK-1) and neurokinin-2, non-opioid (NOP-1), cannabinoid, dopaminergic, and sigma receptors.
Negative_regulation (suppression) of NK-1 associated with gaba, cannabinoid, cough and opioid
3) Confidence 0.37 Published 2009 Journal Handb Exp Pharmacol Section Abstract Doc Link 18825342 Disease Relevance 0.39 Pain Relevance 0.58
Specific receptor subtypes have been associated with the suppression of cough at central sites, including 5-HT1A, opioid (mu, kappa, and delta), GABA-B, tachykinin neurokinin-1 (NK-1) and neurokinin-2, non-opioid (NOP-1), cannabinoid, dopaminergic, and sigma receptors.
Negative_regulation (suppression) of tachykinin neurokinin-1 associated with gaba, cannabinoid, cough and opioid
4) Confidence 0.37 Published 2009 Journal Handb Exp Pharmacol Section Abstract Doc Link 18825342 Disease Relevance 0.39 Pain Relevance 0.58
Cross-desensitization of tachykinin NK1 receptor between hHK-1 and [Sar9,Met(O2)11] SP
Negative_regulation (desensitization) of tachykinin NK1 receptor associated with substance p
5) Confidence 0.36 Published 2010 Journal Respir Res Section Body Doc Link PMC2959027 Disease Relevance 0 Pain Relevance 0.29
A water-soluble, stable dipeptide NK1 receptor-selective neurokinin receptor antagonist with potent in vivo pharmacological effects: S18523.
Negative_regulation (antagonist) of neurokinin receptor associated with antagonist
6) Confidence 0.34 Published 1996 Journal Eur. J. Pharmacol. Section Title Doc Link 8880065 Disease Relevance 0.12 Pain Relevance 0.44
Real-time visualization of the cellular redistribution of G protein-coupled receptor kinase 2 and beta-arrestin 2 during homologous desensitization of the substance P receptor.
Negative_regulation (desensitization) of substance P receptor associated with substance p
7) Confidence 0.26 Published 1999 Journal J. Biol. Chem. Section Title Doc Link 10066824 Disease Relevance 0.10 Pain Relevance 0.39
Ubiquitin-dependent down-regulation of the neurokinin-1 receptor.
Negative_regulation (down-regulation) of neurokinin-1 receptor
8) Confidence 0.20 Published 2006 Journal J. Biol. Chem. Section Title Doc Link 16849335 Disease Relevance 0.18 Pain Relevance 0.39
Protein kinase C-mediated desensitization of the neurokinin 1 receptor.
Negative_regulation (desensitization) of neurokinin 1 receptor associated with kinase c
9) Confidence 0.15 Published 2001 Journal Am. J. Physiol., Cell Physiol. Section Title Doc Link 11287322 Disease Relevance 0.19 Pain Relevance 0.80
Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone

Introduction

Negative_regulation (antagonist) of NK-1 associated with antagonist and dexamethasone
10) Confidence 0.10 Published 2009 Journal Support Care Cancer Section Title Doc Link PMC2726912 Disease Relevance 0 Pain Relevance 0.33
Blocking both the 5-HT3 and NK-1 neurotransmitter receptors has been demonstrated to reduce CINV in patients receiving chemotherapy [5, 17, 26].
Negative_regulation (Blocking) of NK-1 associated with neurotransmitter and vomiting
11) Confidence 0.10 Published 2009 Journal Support Care Cancer Section Body Doc Link PMC2726912 Disease Relevance 1.24 Pain Relevance 0.39
In contrast, a PAF antagonist and a neurokinin-1 receptor antagonist (ie, SP antagonist) significantly reduce supernatant-induced H2O2 production.
Negative_regulation (antagonist) of neurokinin-1 receptor associated with antagonist and substance p
12) Confidence 0.10 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2978390 Disease Relevance 0.28 Pain Relevance 0.73
In contrast, a PAF antagonist and a neurokinin-1 receptor antagonist (ie, SP antagonist) significantly reduce supernatant-induced H2O2 production.
Negative_regulation (antagonist) of neurokinin-1 receptor associated with antagonist and substance p
13) Confidence 0.10 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2978390 Disease Relevance 0.28 Pain Relevance 0.73
Stimulation of IL-6 by SP occurred in a conventional receptor-mediated manner as demonstrated by its differential release by fragments SP 4-11 and SP 1-4 and by the blockage of IL-6 release with the non-peptide, NK-1 receptor antagonist, CP-99 994.
Negative_regulation (blockage) of NK-1 receptor associated with antagonist and substance p
14) Confidence 0.08 Published 1999 Journal Neuropeptides Section Abstract Doc Link 10657523 Disease Relevance 0.33 Pain Relevance 1.15
Central hNK-1 receptor stimulation is also inhibited by the systemic preadministration of 17 as shown by its ability to block an NK-1 agonist-induced foot tapping response in gerbils (IC50 (4 h) = 0.04 +/- 0.006 mg/kg; IC50 (24 h) = 0.33 +/- 0.017 mg/kg) and by its antiemetic actions in the ferret against cisplatin challenge.
Negative_regulation (inhibited) of hNK-1 receptor in foot associated with vomiting and agonist
15) Confidence 0.05 Published 1998 Journal J. Med. Chem. Section Abstract Doc Link 9804700 Disease Relevance 0.18 Pain Relevance 0.32
This report presents data on the safety and tolerability of losartan potassium (losartan), a selective antagonist of the angiotensin II AT-1 receptor, in approximately 2,900 hypertensive patients treated in double-blind clinical trials.
Negative_regulation (antagonist) of AT-1 receptor in AT-1 associated with antagonist and hypertension
16) Confidence 0.01 Published 1995 Journal Am. J. Cardiol. Section Abstract Doc Link 7717281 Disease Relevance 0.76 Pain Relevance 0.18
Carvedilol is a novel non-selective beta-blocker without intrinsic sympathomimetic activity (ISA) and has vasodilating effect through blocking alpha 1 receptor.
Negative_regulation (blocking) of 1 receptor associated with beta blocker
17) Confidence 0.01 Published 2002 Journal Nippon Ronen Igakkai Zasshi Section Abstract Doc Link 11974943 Disease Relevance 0.58 Pain Relevance 0.42
Its antiemetic properties are attributable to aprepitant, which is a selective neurokinin 1 (NK1) receptor antagonist with low affinity for NK2 and NK3 receptors (Watson et al 1998).
Negative_regulation (antagonist) of neurokinin 1 associated with antagonist and vomiting
18) Confidence 0.01 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504061 Disease Relevance 0.82 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox